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Table 1 Clinical and labora- 
tory findings in patients with 
HIV infection and periungual 
erythema 
Patient Age in Focus of >lx* Mode of CDC CD4+T HIV viral HCV 
no. years/sex infection transmission classi- cell count load anti- 
fication in I*1 (copies/ml) bodies 
1 36/m F/T/P yes iv C3 160 23993 pos 
2 40/m T no iv B1 608 3847 pos 
3 35/f T no iv B3 190 793404 pos 
4 32/m T/P no iv/msm C3 100 413 pos 
5 31/f F/P yes iv C3 157 750000 pos 
6 30/f T/P yes iv B2 374 766 pos 
7 38/m F yes iv B3 260 < 244 pos 
8 33/m F no msm A2 370 38515 neg 
9 39/m T no iv B3 45 122085 nd 
10 38/f F yes iv C3 57 15474 prob 
11 58/m T/P no bi C3 5 169254 neg 
12 33/m T no iv C3 30 40271 pos 
13 34/m F no iv C2 260 < 274 pos 
14 31/m T/P yes iv B3 119 < 418 pos 
15 35/m T yes hetero B3 170 206167 ueg 
16 29/f F/P yes iv B2 310 na na 
17 56/m F no msm B2 270 nd neg 
18 57/m T no msm C3 20 45060 neg 
19 28/f F no iv A1 851 1329 pos 
20 33/m F/P no iv C3 135 165616 na 
21 36/f F/T/P yes iv C3 95 4467 pos 
* Diagnosis was established in more than one consultation 
bi, bisexual; CDC, Centers for Disease Control; F, fingers; HCV, hepatitis C virus; hetero, hetero- 
sexual intercourse; iv, intravenous drug abuse; msm, men having sex with men; na, not available; nd, 
not done; neg, negative; P, palmar erythema; pos, positive; prob, probable; T, toes 
these three pat ients per iungual  e ry thema was seen only 
once, and in two of them it d i sappeared  before  the next 
fo l low-up visit. However ,  it is also possib le that the 
serological  test for HCV was falsely negat ive [6]. A l l  
pat ients descr ibed by Pech6re et al. [2] were intrave- 
nous drug users or a lcohol  abusers. Interest ingly,  all of 
our pat ients who were intravenous drug users had posi- 
tive serological  tests for HCV.  There  was no correla-  
t ion between diagnosis of the per iungual  e ry thema nd 
the activity of the H IV  infect ion expressed by the 
actual viral load. 
We conclude that per iungual  e ry thema in H IV- in fected  
pat ients is most often associated with HCV infection 
with or wi thout  concomitant  activity and non-virus- 
induced chronic l iver disease. Other  associat ions are 
suggested, especial ly  in t ransient  per iungual  erythema.  
Possibly, non-organ-speci f ic  autoant ibod ies  in H IV  
infection [7] p lay a role in the pathogenes is  of per iun-  
gual erythema,  ref lect ing the large spectrum of anti- 
bodies found in H IV - in fec ted  patients.  
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Screening for immunity  against the rubel la  virus is an 
essential  part  of the prenata l  care of pregnant  women.  
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Table 1 Rubella-specific anti- 
bodies in the sera of the 
mother and her infant at 
different points in time 
Time antibody test performed Mother Infant 
IgG IgM NT ~' IgG IgM NT 
(IU/ml) (IU/ml) 
First trimester of pregnancy 195 neg 0 n.d. n.d. n.dl 
At birth/delivery 149 neg 0 171 neg 0 
3 months after birth n.d. n.d. n.d. 43 b neg .~_ b 
Before vaccination c 136 neg + + 0 neg 0 
1 month after vaccination 188 neg + + 98 pos + + 
a Neutralisation of rubella virus by serum diluted 1 : 10 
b The child received intravenous immunoglobulins on the second ay of life 
c Mother and infant were vaccinated with live attenuated rubella virus 15 months after birth 
n.d., not done; neg, negative; pos, positive; NT, neutralising antibodies; 0,no neutralisation; +, weak 
neutralisation; ++, strong neutralisation 
Infection of pregnant women who were expected to be 
immune to rubella, with subsequent transmission of the 
pathogen to the foetus, has been reported [1]. We 
present a case of rubella infection in the full-term 
infant of a seropositive mother who lacked neutralising 
antibodies. Our observation challenges immunity 
screening on the basis of mere antibody quantitation. 
A newborn girl was referred to the University Chil- 
dren's Hospital, Zurich on the first day of life because 
she had petechiae, severe thrombocytopenia (13 x 109/1), 
and ventricular extrasystoles. Neonatal alloimmune 
thrombocytopenia was diagnosed. Thrombocytes and 
immunoglobulins were infused. The infant's cardiac 
arrhythmia resolved spontaneously within 2 days. 
Rubella virus was isolated in shell vial cultures of RK- 
13 rabbit kidney cells from throat swabs and urine 
collected on the infant's second day of life. Throat swab 
and urine samples were tested in parallel and in dupli- 
cate; no other samples tested positive for rubella virus 
the same working day. The immunofluorescence assay 
was validated by an inactivated positive control slide; 
no rubella virus was actively cultured in the laboratory 
during the relevant ime period. Thus, mixing of the 
clinical samples is unlikely, and the possibility of labo- 
ratory contamination can be ruled out. The child 
showed no clinical or radiological signs of congenital 
rubella and developed normally. Viral cultures 
performed 3 weeks after birth were negative. 
Rubella antibody determinations were performed 
initially by an external laboratory (IMX system; 
Abbott; Switzerland) and later by our own laboratories 
(Access system; Sanofi Pasteur Diagnostics, Switzer- 
land). The sensitivity and specificity of the appropriate 
IgG tests were 99.7% and 98.9%, respectively, for the 
IMX system and 99.37% and 99.37%, respectively, for 
the Access system. For IgM confirmatory tests, the 
Sorin ix-capture enzyme immunoassay (EIA) (Sorin 
Biomedica; Italy) was used (sensitivity, 99.7%; specif- 
icity, 99.9%). The mother had not been immunised but 
was shown to be seropositive for rubelia virus by both 
laboratories. Sera collected from the mother during the 
first trimester of pregnancy and at delivery and from 
the infant on her second day of life prior to immmuno- 
globulin infusion contained rubella-specific IgG and no 
specific IgM (Table 1). However, none of the sera 
contained neutralising antibodies, as demonstrated in
vitro [2] using the Thomas laboratory strain of rubella 
virus. In contrast, the child's serum collected at age 3 
months showed neutralising activity, which apparently 
originated from the infused immunoglobulins since the 
titre of specific IgG had dropped markedly. Investiga, 
tion of the immune response to live attenuated rubella 
vaccine (strain Wistar-RA 27/3) 15 months after birth 
revealed a slight increase of specific IgG levels in the 
mother and seroconversion for IgM and IgG in the 
child. Moreover, the maternal pre,immunisation serum 
and the post-immunisation sera of both mother and 
child strongly neutralised rubella virus. 
In this case the rubella infection would have gone unre- 
cognised if neonatal alloimmune thrombocytopenia 
with petechiae had not necessitated tests for intrau- 
terine infection. Isolation of rubella virus from two 
different body sites of the 2-day-old infant suggests an 
intrauterine infection, which seems to have been facili- 
tated by the absence of maternal neutralising anti- 
bodies and to have occurred shortly before birth. More- 
over, this infection seems to have resulted in the subse- 
quent appearance of neutralising antibodies in the 
mother. The infused immunoglobulins may have 
contributed to clearing the virus and impeding a sero- 
logic response in the child [3, 41. 
In most countries immunity to rubella virus is deter- 
mined solely on the basis of quantitative IgG antibody 
determination. However, in a few countries such as 
Germany, IgG quantitation is combined with haemag- 
glutination inhibition tests, which may correlate with 
neutralising antibodies [5]. As shown by our case, a 
functional test for determining the appropriate neutral- 
ising capacity of rubella antibodies has merit. 
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However, the addition of a neutralisation test to the 
antibody quantitation test to determine resistance to 
rubella in pregnant women would result in a consider- 
able increase in testing and costs. Because the haemag- 
glutination inhibition test is less demanding with 
respect to time and technical skills, it offers a more 
acceptable cost-to-benefit ratio than the classical 
neutralisation test. Additional studies are required to 
estimate the proportion of women who have EIA-posi- 
tive, non-neutralising antibodies. This proportion may 
depend on the rates of natural infection and vaccina- 
tion and, thus, may vary from country to country. 
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